NVIDIA Stock Price: Why Intel's 45% Plunge Is Important for NVDA Investors
Coinpedia
1h ago
Ai Focus
NVIDIA's market value drops to approximately $4.94 trillion, falling below the $5 trillion mark. The article states that Intel's 45% plunge in October prompted the market to re-examine the chip production capacity and alliance arrangements in the United States, with NVIDIA being at the center of this discussion due to its AI processors and CUDA platforms.
Helpful
No.Help

NVIDIA Stock Price: Why Intel's 45% Plunge Is Important for NVDA Investors

NVIDIA's market value has dropped to around $4.94 trillion, falling below the $5 trillion mark. With Intel experiencing a 45% slump in October, including a 29% drop on a single day, investors are re-evaluating chip stocks. Intel's significant decline has also drawn the market's attention to how future U.S. chip production and alliances will be structured.

NVIDIA is at the heart of this issue, as its AI processors will affect the new factory production capacity and where government support is more likely to flow. The company's revenue from its computing and networking (Compute and Networking) business is approximately $275.4 billion, while its revenue from its graphics (Graphics) business is about $27.6 billion.

A key long-term risk is its CUDA software platform. If a cheaper open-source alternative becomes more widely adopted, large companies may switch directly to manufacturers such as TSMC to custom chips, which would put pressure on NVIDIA's high profit margins.

Tip
$0
Like
0
Save
0
Views 17
HQYC reminds readers to view blockchain rationally, stay aware of risks, and beware of virtual token issuance and speculation. All content on this site represents market information or related viewpoints only and does not constitute any form of investment advice. If you find sensitive content, please click“Report”,and we will handle it promptly。
Submit
Comment 0
Hot
Latest
No comments yet. Be the first!
Related
Ethereum is a "tokenized toll road": Reasons why Joseph Chalom is bullish on ETH
SharpLink CEO Joseph Chalom stated that the long-term logic of ETH is strengthening, and the key is no longer a single catalyst, but rather the speed of blockchain on Wall Street. He proposed three indicators for observation: the supply of stablecoins, the scale of tokenized stocks, and the volume of payment transactions between AI agents.
Coinpedia
·2026-11-03 19:35:50
0
Clarivate Announces Third Quarter 2026 Results, Calling It a Clear Path to Value Creation
Clarivate releases third-quarter results as of September 30, 2026. The company stated that driven by portfolio adjustments and AI-initiated innovation, recurring organic revenue growth has improved, and the annual contract value ( ACV ) of its intellectual property business has resumed growth. Additionally, the company completed the divestiture of its life sciences and healthcare business on October 6 and updated its financial outlook for 2026.
PR Newswire
·2026-11-03 19:24:26
10
Waters Corporation Announces Financial Results for the Third Quarter of 2026
Waters Corporation Announces Financial Results for the Third Quarter of 2026: Revenue of $1.767 Billion, Adjusted Earnings Per Share of $4.10; The Company Upsits Its Annual Revenue and Adjusted Earnings Per Share Guidance for 2026, and Indicates That It Will Provide a Growth Framework for 2027 During the Earnings Call.
PR Newswire
·2026-11-03 19:15:16
19
Clarivate Announces Third Quarter 2026 Results, Claiming to Have Paved a Clear Path for Value Creation
Clarivate Announces Third Quarter 2026 Results, Says Recurrent Organic Revenue Growth Improves Driven by Portfolio Adjustment and AI-Driven Innovation; Intellectual Property Business ACV Resumes Positive Growth; Company Also Updates 2026 Financial Prospects and Completes Sale of Life Sciences and Healthcare Business.
PR Newswire
·2026-11-03 19:15:14
18
Little-known biotech company Genmab sees success with high-risk cancer treatment bets; stock price doubles in three months
Danish biotech company Genmab has seen its stock price double within three months following a series of successful cancer drug trials. The company stated that these breakthroughs have provided new momentum for its strategy to shift from relying on royalty income to taking more control over the ownership and sales revenue of its own developed drugs.
CNBC
·2026-11-03 19:15:12
20
View More